Mechanisms of Breast Cancer Stem Cell Specification and Self-Renewal Mediated by Hypoxia-Inducible Factor 1

被引:7
|
作者
Semenza, Gregg L. [1 ,2 ,3 ]
机构
[1] Johns Hopkins Univ, Inst Cell Engn, Armstrong Oxygen Biol Res Ctr, Sch Med, Baltimore, MD USA
[2] Johns Hopkins Univ, Dept Genet Med, Sch Med, Baltimore, MD USA
[3] Miller Res Bldg,Suite 671,733 N Broadway, Baltimore, MD 21205 USA
关键词
breast cancer stem cells; hypoxia; pluripotency factors; self-renewal; telomerase; ACUTE MYELOID-LEUKEMIA; IN-VITRO PROPAGATION; PROSPECTIVE IDENTIFICATION; TELOMERE LENGTH; TUMOR HYPOXIA; EXPRESSION; SUBPOPULATION; MAINTENANCE; ACTIVATION; PLEXIN-B3;
D O I
10.1093/stcltm/szad061
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Many advanced human cancers contain regions of intratumoral hypoxia, with O2 gradients extending to anoxia. Hypoxia-inducible factors (HIFs) are activated in hypoxic cancer cells and drive metabolic reprogramming, vascularization, invasion, and metastasis. Hypoxia induces breast cancer stem cell (BCSC) specification by inducing the expression and/or activity of the pluripotency factors KLF4, NANOG, OCT4, and SOX2. Recent studies have identified HIF-1-dependent expression of PLXNB3, NARF, and TERT in hypoxic breast cancer cells. PLXNB3 binds to and activates the MET receptor tyrosine kinase, leading to activation of the SRC non-receptor tyrosine kinase and subsequently focal adhesion kinase, which promotes cancer cell migration and invasion. PLXNB3-MET-SRC signaling also activates STAT3, a transcription factor that mediates increased NANOG gene expression. Hypoxia-induced NARF binds to OCT4 and serves as a coactivator by stabilizing OCT4 binding to the KLF4, NANOG, and SOX2 genes and by stabilizing the interaction of OCT4 with KDM6A, a histone demethylase that erases repressive trimethylation of histone H3 at lysine 27, thereby increasing KLF4, NANOG, and SOX2 gene expression. In addition to increasing pluripotency factor expression by these mechanisms, HIF-1 directly activates expression of the TERT gene encoding telomerase, the enzyme required for maintenance of telomeres, which is required for the unlimited self-renewal of BCSCs. HIF-1 binds to the TERT gene and recruits NANOG, which serves as a coactivator by promoting the subsequent recruitment of USP9X, a deubiquitinase that inhibits HIF-1 alpha degradation, and p300, a histone acetyltransferase that mediates acetylation of H3K27, which is required for transcriptional activation. Graphical Abstract
引用
收藏
页码:783 / 790
页数:8
相关论文
共 50 条
  • [31] Deregulation of stem cell self-renewal pathways in cancer
    Clarke, Michael
    CANCER RESEARCH, 2013, 73
  • [32] Self-renewal molecular mechanisms of colorectal cancer stem cells
    Pan, Tianhui
    Xu, Jinghong
    Zhu, Yongliang
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2017, 39 (01) : 9 - 20
  • [33] Stem cell self-renewal, cancer cell proliferation, and aging
    Morrison, Sean J.
    DEVELOPMENTAL BIOLOGY, 2006, 295 (01) : 330 - 330
  • [34] Involvement of hypoxia-inducible factor 1 in human cancer
    Semenza, GL
    INTERNAL MEDICINE, 2002, 41 (02) : 79 - 83
  • [35] Hypoxia-inducible factor 1 in cancer pathogenesis and therapy
    Semenza, G. L.
    EJC SUPPLEMENTS, 2009, 7 (02): : 4 - 4
  • [36] Stem cell self-renewal, cancer cell proliferation, and aging
    Morrison, Sean J.
    AGE, 2007, 29 (2-3) : 127 - 127
  • [37] Inhibiting hypoxia-inducible factor 1 for cancer therapy
    Melillo, Giovanni
    MOLECULAR CANCER RESEARCH, 2006, 4 (09) : 601 - 605
  • [38] A molecular view of stem cell and cancer cell self-renewal
    Tsai, RYL
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2004, 36 (04): : 684 - 694
  • [39] Self-renewal signaling pathways in breast cancer stem cells
    Nalla, Lakshmi Vineela
    Kalia, Kiran
    Khairnar, Amit
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2019, 107 : 140 - 153
  • [40] Identification of self-renewal pathways in breast cancer stem cells
    Bareiss, P.
    Neubauer, H.
    Kopp, H. -G.
    Solomayer, E.
    Wallwiener, D.
    Kanz, L.
    Fend, F.
    Staebler, A.
    Fehm, T.
    Lengerke, C.
    ONKOLOGIE, 2010, 33 : 180 - 180